The Risk of Hysterectomy at Time of Myomectomy at Ain Shams University Hospital: A Retrospective Cohort Study.

Uterine fibroids are the most common benign tumors in reproductive age women affecting up to 80% of women (Havryliuk et al., 2017; Fortin et al., 2018). The cumulative incidence of uterine fibroids by age 50 years can be as high as 70% in white women and more than 80% in black women (Laughlin-Tommaso., 2016).

In many women, myomas may be asymptomatic and are diagnosed incidentally on clinical examination or imaging. 20% to 50% of patients with myoma experience symptoms, such as pelvic pain, heavy menstrual bleeding (HMB), iron deficiency anemia, pressure symptoms, or infertility (Bosteels et al., 2018).Treatment options for uterine fibroids include expectant, medical, or surgical management or by interventional radiology. The ideal treatment should be tailored according to the size, and location of the fibroid, in addition to the patient's age, symptoms, desire for future fertility and physician experience (Evangelisti et al., 2022).

Medical treatment is the hormonal therapy, which can cause shrinkage in the size of myoma, and relieve symptoms but it does not eliminate the disease and that's why if it is effective, it should be used chronically (Evangelisti et al., 2022).

Treatment by interventional radiology could provide an alternative, such as uterine artery embolization (UAE), high-intensity focused ultrasound, or transcervical radiofrequency ablation (Hartmann et al., 2017). In Uterine artery embolization, embolic agents are injected into the arteries that supply the uterus to cut off blood flow to fibroids, causing them to shrink and die that will relieve the symptoms. (Spies JB., 2016) Complications may happen if the blood supply to the ovaries or other organs is reduced. Radiofrequency ablation destroys uterine fibroids and shrinks the blood vessels that feed them, it can be performed through laparoscopy or through transvaginal or transcervical approach(Bradely et al .,2019) In recent years, it has been reported that UAE enables myomectomy with only minimal blood loss. Thereby devascularizing the leiomyoma and allowing for bloodless dissection (McLucas and Voorhees, 2015). This combination of two established procedures is intended to preserve the uterus in women with large and multiple fibroids who are at risk for blood loss including subsequent transfusions as well as conversion to hysterectomy.

Among uterus-preserving therapeutic options, myomectomy is the most widely performed intervention. Yet, for patients with myomas that are large, numerous, or unfavorably located, myomectomy is associated with an elevated risk for intraoperative bleeding and hysterectomy because of tumor-related neovascularization and anatomy distortion (Lethaby et al., 2017; Vargas MV et al., 2017).